Dose conversion (oral to LAI) for Abilify Maintena (aripiprazole monohydrate LAI):
Dose Conversion of Oral Aripiprazole to Aripiprazole LAI | |
PO Dose | LAI/IM Dose |
10 mg aripiprazole | 300 mg Abilify Maintena |
15 mg aripiprazole | 400 mg Abilify Maintena |
20 mg aripiprazole | 600 mg Abilify Maintena |
Recommended available dose formulations include 300 and 400 mg pre-filled vial kits (PI recommended maximum 400 mg). | |
Dose conversion (oral to LAI) for Aristada (aripiprazole lauroxil LAI):
Dose Conversion of Oral Aripiprazole to Aripiprazole LAI | |
PO Dose | LAI/IM Dose |
10 mg aripiprazole | 441 mg Aristada every 4 weeks |
15 mg aripiprazole | 662 mg Aristada every 4 weeks |
15 mg aripiprazole | 882 mg Aristada every 6 weeks |
15 mg aripiprazole | 1064 mg Aristada every 8 weeks |
20 mg aripiprazole | 882 mg Aristada every 4 weeks |
Recommended available dose formulations include 441, 662, 882, and 1064 pre-filled vial kits. | |
Dose conversion (oral to LAI) for Prolixin Decanoate (fluphenazine decanoate):
Dose Conversion of Oral Fluphenazine to Fluphenazine Decanoate LAI | |
PO Dose - Fluphenazine | LAI/IM Dose - Fluphenazine Decanoate |
Initial LAI dose | Suggested 6.25 mg every 2 weeks |
10 mg daily | 12.5 mg (0.5 ml) every 3 weeks |
20 mg daily | 25 mg (1 ml) every 3 weeks |
30 mg daily | 37.5 mg (1.5 ml) every 3-6 weeks |
40 mg daily | 50 mg (2 ml) every 3-6 weeks |
Typical dose: 6.25-25 mg every 2-4 weeks. | |
Dose conversion (oral to LAI) for Haldol Decanoate (haloperidol decanoate):
Dose Conversion of Oral Haloperidol to Haloperidol Decanoate LAI | |
PO Dose - Haloperidol | LAI/IM Dose - Haloperidol Decanoate |
Initiate LAI dose – for elderly, debilitated, or stable on low doses of oral haloperidol | 10-15x PO dose |
Maintenance LAI dose – for stabilized or elderly patients | 10-15x PO dose every 4 weeks |
Initiate LAI dose – for patients with high relapse risk / higher dose | 20x PO dose |
Maintenance LAI dose – for patients with high relapse risk / higher dose | 10-15x PO dose every 4 weeks |
General conversion formula: For each 5 mg/day oral, give 50-75 mg Decanoate every 4 weeks. | |
Dose conversion (oral to LAI) for Invega Sustenna (paliperidone palmitate LAI), Invega Trinza (paliperidone palmitate 12-week LAI), or Invega Hafyera (paliperidone palmitate 6-month LAI):
Paliperidone Conversion from Oral to LAI Formulations | |||
PO Dose | LAI/Invega Sustenna Dose | LAI/Invega Trinza* | LAI/Invega Hafyera** |
<3 mg Paliperidone | 39 mg Invega Sustenna every 4 weeks | N/A | N/A |
3 mg Paliperidone | 78 mg Invega Sustenna every 4 weeks | 273 mg Invega Trinza every 12 weeks | N/A |
6 mg Paliperidone | 117 mg Invega Sustenna every 4 weeks | 410 mg Invega Trinza every 12 weeks | N/A |
9 mg Paliperidone | 156 mg Invega Sustenna every 4 weeks | 546 mg Invega Trinza every 12 weeks | 1,092 mg Invega Hafyera every 6 months |
12 mg Paliperidone | 234 mg Invega Sustenna every 4 weeks | 819 mg Invega Trinza every 12 weeks | 1,560 mg Invega Hafyera every 6 months |
*Stabilization with at least four months (4 injections) of Invega Sustenna required prior to initiation of Invega Trinza. **Stabilization with at least four months (4 injections) of Invega Sustenna or at least one three month cycle (1 injection) of Invega Trinza prior to initiation of Invega Hafyera. If administering a strong CYP3A4/P-glycoprotein inducer, considering managing the patient using Paliperidone extended-release tablet. References: 1. Stahl, S.M. (2017). The prescribers guide: Stahl’s essential psychopharmacology (6th ed.). New York: Cambridge University Press. 2. American Psychiatric Association. (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. American Psychiatric Association Publishing. https://doi.org/10.71176/appi.books.9780890424841 3. INVEGA SUSTENNA USPI, Section 2.8: Instructions for Use; Section 17: How Supplied/Storage and Handling 4. INVEGA TRINZA USPI, Section 2.2: Schizophrenia 5. INVEGA HAFYERA USPI, Section 2.4: Instruction for Preparation and Administration | |||
Dose conversion (oral to LAI) for Risperdal Consta (risperidone microspheres LAI):
Dose Conversion of Oral Risperidone to Risperidone Microspheres LAI | |
PO Dose | LAI/IM Dose |
1 mg daily | 12.5 mg (injection volume of 2 ml) every 2 weeks |
2-3 mg daily | 25 mg (injection volume 2 ml) every 2 weeks |
3-5 mg daily | 37.5 mg (injection volume 2 ml) every 2 weeks |
4-5 mg daily | 50 mg (injection volume 2 ml) every 2 weeks |
Recommended available dose formulations include 12.5 mg, 25 mg, 37.5 mg, and 50 mg pre-filled vial kits. | |
Dose conversion (oral to LAI) for Perseris (risperidone subcutaneous LAI):
Dose Conversion of Oral Risperidone to Risperidone Subcutaneous LAI | |
PO Dose | LAI/SC Dose |
3 mg daily | 90 mg every 4 weeks |
4 mg daily | 120 mg every 4 weeks |
Recommended available dose formulations include 90 mg and 120 mg pre-filled vial kits. | |
Dose conversion (oral to LAI) for Zyprexa Relprevv (olanzapine LAI):
Dose Conversion of Oral Olanzapine to Olanzapine LAI | ||
PO Dose | LAI/IM Dose – Initial 8 weeks | LAI/IM Dose – Maintenance |
10 mg daily | 210mg every 2 weeks or | 150 mg every 2 weeks or |
15 mg daily | 300 mg every 2 weeks | 210 mg every 2 weeks or |
20 mg daily | 300 mg every 2 weeks | 300 mg every 2 weeks |
Recommended available dose formulations include 210 mg, 300 mg and 405 mg pre-filled powder for suspension vial kits. | ||
If you would like more information on this topic, or would like to provide any feedback, please send us a message using our consultation system. Be sure to let us know about which tip you are writing. We would love to hear from you, and the consultation system is free to use and confidential. Thank you!